Interactions between viruses in transplant recipients

Clinical Infectious Diseases

Volumn 40, Issue 3, 2005, Pages 430-436

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FUNCTION; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 6; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; VIRUS INFECTION; VIRUS VIRULENCE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION; VIRUS DISEASES;

EID: 13444255965     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427214     Document Type: Review

References (76)

1. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308:307-13.
2. Kristoffersen AK, Johnsen JI, Seternes M, Rollag H, Degre M, Traavik T. The human polyomavirus BK T antigen induces gene expression in human cytomegalovirus. Virus Res 1997; 52:61-71.
3. Verdonck LF, De Gast GC. Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation? Lancet 1984; 1(8383):932-5.
4. Kelsey DK, Overall JC Jr, Glasgow LA. Correlation of the suppression of mitogen responsiveness and the mixed lymphocyte reaction with the proliferative response to viral antigen of splenic lymphocytes from cytomegalovirus-infected mice. J Immunol 1978; 121:464-70.
5. Fiche M, Soulillou JP, Bignon JD, Billaudel S, Guenel J. T lymphocyte monitoring in kidney transplant recipients undergoing cytomegalovirus infection or rejection episodes. Transplantation 1984; 37:421-3.
6. Sell MS, Bale JF Jr, Giller RH. T-lymphocyte subpopulations and function during murine cytomegalovirus infection. Pediatr Res 1985; 19:583-7.
7. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10:S460-7.
8. Murayama T, Mulkaida N, Khabar KS, Matsushima K. Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection. J Leukoc Biol 1998; 64:62-7.
9. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: an emerging pathogen. Emerg Infect Dis 1999; 5:353-66.
10. Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS, Huang ES. Multiple mechanisms are implicated in regulation of NF-κB activity during human cytomegalovirus infection. Proc Natl Acad Sci USA 1993; 90:1107-11.
11. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14:136-8.
12. Laursen A, Mogensen S, Andersen H, Andersen P, Ellermann-Erksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001; 123:239-46.
13. Lusso P, Secchiero P, Crowley RW, Garzino-Demo A, Berneman ZN, Gallo RC. CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proc Natl Acad Sci USA 1994; 91:3872-6.
14. + mature human T cell populations and clones by human herpesvirus 6. J Immunol 1991; 147:685-91.
15. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995; 85:1263-71.
16. Horvat RT, Parmely MJ, Chandran B. Human herpesvirus 6 inhibits the proliferative responses of human peripheral blood mononuclear cells. J Infect Dis 1993; 167:1247-80.
17. Agut H. Puzzles concerning the pathogenicity of human herpesvirus 6. N Engl J Med 1993; 329:203-4.
18. Knox KK, Carrigan DR. In vitro suppression of marrow progenitor cell differentiation by human herpesvirus-6 infection. J Infect Dis 1992; 165:925-9.
19. Anderson RA, Liu X, Compels A. Definition of a human herpesvirus-6 beta herpesvirus-specific domain in glycoprotein gH that governs interaction with glycoprotein gL: substitution of human cytomegalovirus glycoproteins permits group-specific complex formation. Virology 1996; 217:517-26.
20. Kaye JF, Compels UA, Minson AC. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV uL115 gene product. J Gen Virol 1992; 73:2693-8.
21. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178:1783-6.
22. Dockrell DH, Smith TF, Paya CV. Human herpesvirus 6. Mayo Clin Proc 1999; 74:163-70.
23. Ratnamohan VM, Chapman J, Howse H, et al. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 1998; 66:877-82.
24. Mendez JC, Dockrell DH, Espy MJ, et al. Human β-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183:179-84.
25. Lautenschlager I, Hockerstedt K, Linnavuori K, Taskinen E. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998; 26:702-7.
26. Rogers J, Singh N, Carrigan DR, et al. Clinical relevance of human herpesvirus-6 infection in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and impact on outcome. Transplantation 2000; 69:2566-73.
27. Humar A, Malkan G, Moussa G, Greig P, Levy G, Mazzulli T. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181:1450-3.
28. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous β-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17:114-20.
29. Kirn E, Krueger E, Boehmer S, Klussmann JP, Krueger GRF. In vitro cytobiological effects of human herpesviruses 6 and 7: immunohistological monitoring of apoptosis, differentiation, and cell proliferation. Anticancer Res 1997; 17:4623-32.
30. Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2004; 69:2400-4.
31. Osman HK, Peiris JSM, Taylor CE, Karlberg JPE, Madeley CR. Correlation between the detection of viral DNA by the polymerase chain reaction in peripheral blood leukocytes and serological responses to human herpesvirus 6, human herpesvirus 7, and cytomegalovirus in renal allograft recipients. J Med Virol 1997; 53:288-94.
32. Chan PKS, Peiris JSM, Yuen KY, et al. Human herpesvirus-6 and human herpervirus-7 infections in bone marrow transplant recipients. J Med Virol 1997; 53:295-305.
33. Lowance D, Neumayer HH, Legendre CM, et al. Valganciclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340:1462-70.
34. Ablashi DV, Josephs SF, Buchbinder A, et al. Human G-lymphotropic virus (human herpesvirus-6). J Virol Methods 1998; 21:29-48.
35. Flamand L, Stefanescu I, Ablashi DV, Menezes J. Activation of Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol 1993; 67:6768-77.
36. Schonnebeck M, Krueger GRF, Braun M, et al. Human herpesvirus-6 infection may predispose cells to superinfection by other viruses. In Vivo 1991; 5:255-63.
37. Aalto SM, Linnavuori K, Peltola H, et al. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998; 56:186-91.
38. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346-53.
39. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia. Transplantation 1997; 64:721-6.
40. Chopra KB, Demetris AJ, Blakolmer D, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76:1487-91.
41. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-9.
42. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70:1454-8.
43. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16:92-6.
44. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2:461-6.
45. Eckels DD, Wang H, Bian TH, Tabatabai N, Gill JC. Immunobiology of HCV infection: the role of CD4 T cells in HCV infection. Immunol Rev 2000; 174:90-7.
46. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19:129-40.
47. Zein NN. Tumor necrosis factor gene promoter polymorphism and recurrent hepatitis C after liver transplantation, the missing link to pathogenesis or a causal association? Liver Transplant 2000; 381-3.
48. Heilbronn R, Albrecht I, Stephen S, Burkle A, zur Hausen H. Human cytomegalovirus induced JC virus DNA replication in human fibroblasts. Proc Natl Acad Sci USA 1993; 90:11406-10.
49. Held TK, Beil SS, Nitsche A, et al. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 2000; 26:347-50.
50. Puliyanda DP, Amet N, Hilo L, et al. CMV infection and HLA class I mismatch are significant risk factors for polyoma virus BK nephropathy. Am J Transplant 2004; 4:198.
51. Singh N, Wagener MM, Gayowski T. Seasonal pattern of early mortality and infectious complications in liver transplant recipients. Liver Transpl 2001; 7:884-9.
52. Robinson LE, Hilinski J, Graham F, Shaw M, Nesheim S, Hymes L. Cytomegalovirus (CMV) disease in pediatric renal transplant recipients: identification of a novel risk factor [abstract 767]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:611.
53. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64:262-8.
54. Davis MG, Kenney SC, Kamine J, Pagano JS, Huang ES. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84:8642-6.
55. Gendelman HE, Phelps W, Feigenbaum L, et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986; 83:9759-63.
56. Mosca JD, Bednarik DP, Raj NB, et al. Herpes simplex virus type-1 can activate transcription of latent human immunodeficiency virus. Nature 1987; 325:67-70.
57. Mercader M, Nickoloff BJ, Foreman KE. Induction of human immunodeficiency virus 1 replication by human herpesvirus B. Arch Pathol Lab Med 2001; 125:785-9.
58. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-8.
59. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30:S77-84.
60. Soto B, Sanchez-Quijario A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C virus with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
61. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1. J Infect Dis 2000; 181:442-8.
62. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-20.
63. Rappaport D, Engelhard D, Tagger G, Or R, Frenkel N. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002; 4:10-6.
64. Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:595-8.
65. Zerr DM, Gupta D, Huang ML, Carter, R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hemataopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:309-17.
66. Zerr DM, Gooley TA, Young L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 33:763-71.
67. Lautenschlager I, Linnavuori K, Lappalainen M, Suni I, Hockerstedt K. HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl Int 2000; 13:S351-3.
68. Wang FZ, Linde A, Hagglund H, Testa M, Locasciulli A, Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999; 28:562-8.
69. De Bolle L, Michel D, Mertens T, et al. Role of the human herpesvirus 6 U69-encoded kinase in the phosphorylation of ganciclovir. Mol Pharmacol 2002; 62:714-21.
70. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Oral ganciclovir and valganciclovir prophylaxis may prevent reactivation of non-β herpesviruses in cytomegalovirus (CMV) D+/R-solid organ (SOT) transplant patients. Am J Transplant 2004; 4:337.
71. Humar A, Moussa G, Mazzulli T, et al. An assessment of adenovirus infection in a large cohort of solid organ transplant recipients. Am J Transplant 2004; 4:425.
72. Metcalf JP, Monick MN, Stinski MF, Hunninghake GW. Adenovirus EIA 135 gene product upregulates the cytomegalovirus major immediate early promoter. Am J Respir Cell Mol Biol 1994; 10:448-52.
73. Halary F, Amara A, Lortat-Jacob H, et al. Human cytomegalovirus binding to DC-sign is required for dendritic cell infection and target cell trans-infection. Immunity 2002; 17:653-64.
74. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virious. Blood 2001; 97:994-1000.
75. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3915-22.
76. Walter EA, Greenbrg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.